Brief: Tetralogic announces pacts to restructure convertible debt

Tetralogic Pharmaceuticals

02/11/2016 20:30

Nov 2 (Reuters) - Medivir Ab  MVIRb.ST  
    * Tetralogic announces agreements to sell smac mimetic and 
hdac inhibitor assets to medivir and to restructure its 
convertible senior notes and delisting of common stock 
    * Tetralogic Pharmaceuticals Corp - in consideration medivir 
is expected to pay $12 million in cash upon closing of 
transaction 
    * Tetralogic Pharmaceuticals Corp - in consideration medivir 
is expected to pay future milestones of up to $153 million 
    * Tetralogic Pharmaceuticals Corp -  agreed to use $12 
million cash proceeds received at closing of sale to redeem $12 
million senior notes 
    * Tetralogic Pharmaceuticals-will be terminating all 
remaining employees, with all terminations expected to be 
completed no later than december 1, 2016 
    * Tetralogic Pharmaceuticals Corp - board determined to 
voluntarily delist  and deregist 
    * Tetralogic announces agreements to sell smac mimetic and 
hdac inhibitor assets to medivir and to restructure its 
convertible senior notes and delisting of common stock 
 
Source text for Eikon:  ID:nGNXNKNYCa  
Further company coverage:  MVIRb.ST  
 
 ((Bangalore.newsroom@thomsonreuters.com;))